SS-31 (Elamipretide) Research Index

Mitochondria dysfunction and increased expression of WNT5A and BNIP3 in tenocytes obtained from patients with tendinopathy.

Nakagawa Y, Okazaki Y, Carballo CB et al.

JSES Int·2026·Human·PubMed →

Patient self-selection does not influence postoperative improvements in pain, function, or satisfaction in ream-and-run arthroplasty patients.

Suttmiller AMB, Snyder BA, Carofino BC

J Shoulder Elbow Surg·2026·Human·Osteoarthritis·PubMed →

RePOWER: An International, Prospective, Non-Interventional Registry of Patients With Primary Mitochondrial Myopathy.

Karaa A, Goldstein A, Cohen BH et al.

Clin Genet·2026·Human·PubMed →

Protective Effect of Mitochondria-Targeted Polydopamine Nanoparticles in Alleviating Hepatic Ischemia-Reperfusion Injury.

Huang Y, Cui X, You J et al.

ACS Nano·2026·Animal·PubMed →

Peroxiredoxin Ⅲ safeguards cardiac function against doxorubicin by regulating mitochondrial quality control via H(2)O(2) detoxification.

Park JW, Jang SY, Kim MY et al.

Redox Biol·2026·Animal·PubMed →

Mitochondria-Targeted Liposomes Boost Thermogenesis for Adipose Tissue Regulation.

Tian S, Xie H, Zhong Q et al.

Adv Healthc Mater·2026·Animal·PubMed →

Breaking a mitochondrial danger-STING feed-forward amplifier preserves alveolar-capillary architecture and dampens interferon-chemokine signaling in acute lung injury.

Elmorsy EA, Amer MM, Hamad RS et al.

Tissue Cell·2026·Animal·PubMed →

Restoring cardiolipin homeostasis mitigates cerebral ischemia-reperfusion injury by suppressing ATG5-mediated neuronal autophagy-dependent ferroptosis.

Dong W, Zhang W, Huang L et al.

J Adv Res·2026·Animal·PubMed →

Mechanisms of Anti-Oxidants, N-Acetylcysteine and Elamipretide (SS-31), on Ozone-Induced Airway Hyperresponsiveness and Mucus Hypersecretion.

Xie M, Weng J, Li C et al.

Lung·2026·Animal·PubMed →

Effects of asprosin on high-fat diet-induced liver injury in rats: a histopathological, immunohistochemical, and molecular study.

Karadeniz Saygili S, Akcilar R

Folia Morphol (Warsz)·2026·Animal·Liver Protection·PubMed →

Association of hippocampus, entorhinal cortex, and amygdala with thyroid function: a bilateral volumetric analysis.

Hallab A, Alzheimer’s Disease Neuroimaging Initiative (ADNI)

Thyroid Res·2026·Animal·PubMed →

Early targets and progressive deterioration in cardiac performance in response to chronically modified cardiac troponin I.

Ravichandran VS, Schatz TM, Lavey E et al.

Am J Physiol Heart Circ Physiol·2026·Animal·PubMed →

Disruption of hippocampal mitochondrial function underlies opioid-induced postoperative cognitive dysfunction in aged rats.

Muscat SM, Deems NP, Alvarez BD et al.

bioRxiv·2026·Animal·PubMed →

MK-3903 alleviates myocardial ischemia/reperfusion injury and mitochondrial dysfunction associated with AMKP-PGC-1α signaling.

Li PB, Gao J, Li HH et al.

Biochem Biophys Res Commun·2026·Animal·PubMed →

HA/CD44-SS31 Mitochondrial Targeting of Manganese Oxide Nanozymes for Ischemia-Reperfusion-Induced Acute Kidney Injury Therapy.

Lin Z, Zhou E, Zhang D et al.

ACS Nano·2026·Animal·PubMed →

The mitochondria-targeted peptide HDAP2 reduces mitochondrial loss and retinal ganglion cell degeneration after optic nerve injury.

MacNeil MA, Arain S, Mentor W et al.

Neuroscience·2026·Animal·Neuroprotection·PubMed →

SS-31 improves the quality of maternally aged oocytes by ameliorating mitochondrial function and metabolism.

Xiong D, Zhang Y, Wei J et al.

J Ovarian Res·2026·Animal·PubMed →

Mitochondrial Targeting by Elamipretide Improves Myocardial Bioenergetics Without Translating into Functional Benefits in HFpEF.

Schauer A, Jahn D, Vahle B et al.

Int J Mol Sci·2026·Animal·PubMed →

Synergistic mitochondrial homeostasis regulation and cholinergic circuits reconstruction via a one-step synthesized multifunctional hydrogel facilitates spinal cord injury repair.

Luo Y, Jiang P, Huang D et al.

Bioact Mater·2026·Animal·PubMed →

Cuproptosis of bronchial epithelial cells triggers airway remodeling in chronic asthma.

Wang M, Liu C, Li Z et al.

Sci Rep·2026·Animal·PubMed →

Energy-replenishing, mitochondria-targeted hydrogel microspheres mitigate sarcopenia via cellular senescence amelioration.

Bao W, Liu S, Du C et al.

J Control Release·2026·Animal·Longevity·PubMed →

Elamipretide Improves Mitochondrial Function in Mitochondrial Trifunctional Protein-Deficient Mice and Human Fibroblasts.

Vieira Neto E, Wang M, Szuminsky AJ et al.

J Inherit Metab Dis·2026·Animal·Tissue Remodeling, Muscle Recovery·PubMed →

NNT inhibits microglial activation via mitochondrial oxidative stress in spinal cord injury.

Li M, Gu Q, Fan Z et al.

Neurosci Lett·2026·Animal·PubMed →

Elamipretide: The first cardiolipin-directed mitochondrial therapeutic for Barth syndrome approved under accelerated approval.

Zhao C, Zhuang X, Gao J

Drug Discov Ther·2026·Animal·PubMed →

Elamipretide Hydrochloride.

Am J Health Syst Pharm·2026·Animal·PubMed →

Real-world disease burden and health care resource utilization for patients with Barth syndrome.

Marjoram L, Huang Y, Koenig MK et al.

J Med Econ·2025·Human·PubMed →

Elamipretide in the Management of Barth Syndrome: Current Evidence and a Case Report.

Jacob N, Schecter D, Marshall M et al.

Mol Genet Metab·2025·Human·PubMed →

Cardiac pathology in a patient with a novel pathogenic variant c.703del (p.Ile235SerfsTer4) of the TAFAZZIN gene.

Prasanpanich M, Husain M, Halnon NJ et al.

Cardiovasc Pathol·2025·Human·PubMed →

Initial Psychometric Evaluation of the Barth Syndrome Symptom Assessment (BTHS-SA) for Adolescents and Adults in a Phase 2 Clinical Study.

Gwaltney C, Shields A, Love E et al.

Orphanet J Rare Dis·2025·Human·PubMed →

Examination of mitochondria- and inflammasome-mediated mechanisms of clozapine-induced myocarditis using patient-derived iPSC cardiomyocytes.

Vaziri N, Shutt TE, Karim W et al.

Mol Psychiatry·2025·Human·Anti-Inflammatory·PubMed →

Expanded-access use of elamipretide in a newborn with Barth syndrome: a case report.

Ortmann L, Velasco D, Cole J

Eur Heart J Case Rep·2025·Human·PubMed →

ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preservation.

Ehlers JP, Hu A, Boyer D et al.

Ophthalmol Sci·2025·Human·PubMed →

Targeting ANT1 to regulate PINK1/Parkin-mediated mitophagy is an effective treatment of trauma-induced tendon heterotopic ossification.

Li G, Li T, Deng Y et al.

J Orthop Translat·2025·Animal·PubMed →

Mitochondria-Targeted Peptides and Bilayer Composition Modulate Membrane Electroporation under Elevated Electrochemical Stress.

Tamucci JD, Zweifach A, Alder NN et al.

Langmuir·2025·Animal·PubMed →

Targeted Delivery of AGO-2 to Myocardial Mitochondria via Functionalized Nanoparticles Attenuates Oxidative Stress in Diabetic Cardiomyopathy.

Du W, Jiang Y, Wu L et al.

ACS Appl Mater Interfaces·2025·Animal·PubMed →

Endothelial Glycocalyx Degradation as a Mediator of Neuroinflammation and Cognitive Impairment in Aged Rats: Protective Role of SS-31.

Kan MH, Liu Y, Meng FQ et al.

Mol Neurobiol·2025·Animal·Longevity, Anti-Inflammatory·PubMed →

Effects of imeglimin on mitochondrial functions and ischemic brain damage in young and aging rats.

Paskeviciene E, Skemiene K, Pampuscenko K et al.

J Pharmacol Sci·2025·Animal·Longevity·PubMed →

Mitochondrial dysfunction drives age-related degeneration of the thoracic aorta.

Dhanekula AS, Harrison BR, Pharaoh G et al.

Geroscience·2025·Animal·PubMed →

Expanded-access use of elamipretide in a critically ill patient with Barth syndrome.

Goldstein AC, Pantano C, Redko M et al.

Genet Med Open·2024·Human·PubMed →

Expanded-Access Use of Elamipretide Improves Quality of Life in Patients With Rare Mitochondrial Disorders Characterized by Ophthalmic Symptoms: A Case Series.

Ansari S, Koenig MK

Clin Case Rep·2024·Human·PubMed →

Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial.

Karaa A, Bertini E, Carelli V et al.

Orphanet J Rare Dis·2024·Human·PubMed →

Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM.

Sherrod CF 4th, Saberi S, Nassif ME et al.

J Am Coll Cardiol·2024·Human·PubMed →

Expanded-access use of elamipretide in a patient with membrane protein-associated neurodegeneration.

Patino J, Clearman AH, Miller L et al.

Clin Case Rep·2024·Human·PubMed →

Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.

Thompson WR, Manuel R, Abbruscato A et al.

Genet Med·2024·Human·PubMed →

Elamipretide Topical Ophthalmic Solution for the Treatment of Subjects with Leber Hereditary Optic Neuropathy: A Randomized Trial.

Karanjia R, Sadun AA

Ophthalmology·2024·Human·PubMed →

Validation of a Reduced Set of High-Performance Triggers for Identifying Patient Safety Incidents with Harm in Primary Care: TriggerPrim Project.

Garzón González G, Alonso Safont T, Conejos Míquel D et al.

J Patient Saf·2023·Human·PubMed →

Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.

Karaa A, Bertini E, Carelli V et al.

Neurology·2023·Human·PubMed →

Identifying responders to elamipretide in Barth syndrome: Hierarchical clustering for time series data.

Van den Eynde J, Chinni B, Vernon H et al.

Orphanet J Rare Dis·2023·Human·PubMed →

Use of Elamipretide in patients assigned treatment in the compassionate use program: Case series in pediatric patients with rare orphan diseases.

Koenig MK, Russo SN, McBride KL et al.

JIMD Rep·2023·Human·PubMed →

Psychometric performance of the Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) in a randomized, double-blind, placebo-controlled crossover study in subjects with mitochondrial disease.

Gwaltney C, Stokes J, Aiudi A et al.

J Patient Rep Outcomes·2022·Human·PubMed →